| DC Field | Value | Language |
|---|
| dc.contributor.author | Koklin, I. S. | - |
| dc.contributor.author | Danilenko, L. M. | - |
| dc.date.accessioned | 2022-04-24T10:22:20Z | - |
| dc.date.available | 2022-04-24T10:22:20Z | - |
| dc.date.issued | 2019 | - |
| dc.identifier.citation | Koklin, I.S. Combined use of arginase II inhibitors and tadalafil for the correction of monocrotaline pulmonary hypertension / I.S. Koklin, L.M. Danilenko // Research Results in Pharmacology. - 2019. - Vol. 5, № 3.- P. 79-85. - Doi: 10.3897/rrpharmacology.5.39522. - Refer.: p. 84. | ru |
| dc.identifier.uri | http://dspace.bsu.edu.ru/handle/123456789/46311 | - |
| dc.description.abstract | The concept of the regulatory role of endothelium in the pathogenesis of pulmonary hypertension (PH) is fundamental. To study the protective effects of the selective arginase II inhibitors L207-0525 and L327-0346 in combination with tadalafil in a monocrotaline model of pulmonary hypertension in rats | ru |
| dc.language.iso | en | ru |
| dc.subject | medicine | ru |
| dc.subject | pharmacology | ru |
| dc.subject | monocrotaline | ru |
| dc.subject | pulmonary hypertension | ru |
| dc.subject | arginase II inhibitors | ru |
| dc.subject | tadalafil | ru |
| dc.title | Combined use of arginase II inhibitors and tadalafil for the correction of monocrotaline pulmonary hypertension | ru |
| dc.type | Article | ru |
| Appears in Collections: | Vol. 5, № 3
|
